The 5th Annual iPSC Drug Development Summit returned to Boston in 2025 as your longest standing and most definitive platform for uniting iPSC-based drug developers across the value chain, from R&D right through to CMC, to accelerate the development of genetically stable, clinically efficacious and scalable iPSC cell therapies.

The Summit tailored learning across 2 tracks of content, with a Preclinical stream, and Process Development & CMC stream – where attendees took a deep-dive into novel humanized mouse models to aid a greater translational leap into the clinic, or explore novel bioreactors for new methods of iPSC generation.

Also in attendance were the trailblazers of the iPSC field, including Aspen Neuroscience, Sana Biotech, Novo Nordisk, and BlueRock Therapeutics, as they unveiled practical strategies for engineering allo-evasive cell products, overcoming reprogramming and scalability challenges, and addressing regulatory complexities from R&D through to commercialization. Attendees learnt how leaders were optimizing iPSC line selection, advancing GMP-compliant manufacturing, and deploying novel genetic and encapsulation-based tools to stabilize differentiation outcomes and maximize clinical impact.

With therapeutic applications spanning oncology, neurology, immunology, and regenerative medicine, this summit equipped you to navigate the most pressing hurdles in iPSC development - from managing donor variability and ensuring genomic stability, to aligning QC testing with GMP standards. You gained actionable insights on optimizing iPSC-derived T cell maturation, tackling immunogenicity, standardizing differentiation protocols, and validating final cell identities to streamline delivery, satisfy regulators, and accelerate your path to clinic.